Search results
Your search for CNAPS returned no results
Showing 1 to 50 of 56 results for caps
Showing 1 to 50 of 56 results for caps
Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections.
View recommendations for MTG62Show all sections
Manchester CAPS: A Sustainable Implementation of Incredible Years
Service (CAPS) Early Intervention Published date: December 2014 CAPS is a jointly
This guideline covers the main risk factors linked with cardiovascular disease: poor diet, physical inactivity, smoking and excessive alcohol consumption. It aims to reduce the high incidence of cardiovascular disease. This, in turn, will help prevent other major causes of death and illness, such as type 2 diabetes and many cancers.
This quality standard covers services for domestic violence and abuse in adults and young people (aged 16 and over). It includes identifying and supporting people experiencing domestic violence or abuse, as well as support for those who carry it out. It also covers children and young people (under 16) who are affected by domestic violence or abuse that is not carried out against them. It describes high-quality care in priority areas for improvement.
View quality statements for QS116Show all sections
Sections for QS116
- Introduction
- List of quality statements
- Quality statement 1: Asking about domestic violence and abuse
- Quality statement 2: Response to domestic violence and abuse
- Quality statement 3: Referral to specialist support services for people experiencing domestic violence or abuse
- Quality statement 4: Referral to specialist services for people perpetrating domestic violence or abuse
- Using the quality standard
- Diversity, equality and language
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.
This quality standard covers contraception for women, including emergency contraception. It describes high-quality care in priority areas for improvement.
View quality statements for QS129Show all sections
Curos for preventing infections when using needleless connectors (MTG44)
Evidence-based recommendations on Curos for preventing infections when using needleless connectors.
View recommendations for MTG44Show all sections
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.
Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course of chemotherapy.
View recommendations for TA515Show all sections
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Endocuff Vision for assisting visualisation during colonoscopy (MTG45)
Evidence-based recommendations on Endocuff Vision for assisting visualisation during colonoscopy.
View recommendations for MTG45Show all sections
Evidence-based recommendations on atezolizumab (Tecentriq) for previously treated locally advanced or metastatic urothelial carcinoma in adults.
BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis (MIB32)
NICE has developed a medtech innovation briefing (MIB) on BD MAX Enteric Bacterial Panel for identifying pathogens in contagious gastroenteritis .
NHSE. Complex schemes Complex schemes include: outcomes-based dose caps rebates upfront free stock. The complexity of these schemes...
NICE has developed a medtech innovation briefing (MIB) on the needle-free arterial non-injectable connector .
Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years) (TA38)
Evidence-based recommendations on inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years).
NICE has developed a medtech innovation briefing (MIB) on Neon EEG electrode for EEG monitoring in newborns .
Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine. These drugs are for people with ovarian cancer that has come back some time after it was first treated.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Evidence-based recommendations on therapeutic hypothermia with intracorporeal temperature monitoring for hypoxic perinatal brain injury. This involves cooling either the baby's head or whole body to prevent brain damage.
View recommendations for IPG347Show all sections
Sections for IPG347
Flexible endoscopic treatment of a pharyngeal pouch (IPG513)
Evidence-based recommendations on flexible endoscopic treatment of a pharyngeal pouch. This involves improving swallowing by widening the neck of the pouch so that food does not collect in it.
Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach (IPG717)
Evidence-based recommendations on endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach. This involves removing a tumour using an endoscope and forceps. The aim is to remove the tumour without the need for open surgery.
View recommendations for IPG717Show all sections
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.
Evidence-based recommendations on pembrolizumab (Keytruda) for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy in adults.
Evidence-based recommendations on eribulin (Halaven) for locally advanced or metastatic (secondary) breast cancer in adults who have had 2 or more courses of chemotherapy.
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (TA909)
Evidence-based recommendations on lorlatinib (Lorviqua) for untreated ALK-positive advanced non-small-cell lung cancer in adults.
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (TA208)
Evidence-based recommendations on trastuzumab (Herceptin) for treating HER2-positive metastatic gastric cancer in adults.
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.
Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab (TA629)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for follicular lymphoma that has not responded or has progressed up to 6 months after treatment with rituximab or a rituximab-containing regimen in adults.
NICE has developed a medtech innovation briefing (MIB) on point-of-care and home faecal calprotectin tests for monitoring treatment response in inflammatory bowel disease .
Endoscopic full thickness removal of non-lifting colonic polyps (IPG580)
Evidence-based recommendations on endoscopic full thickness removal of non-lifting colonic polyps. This involves using a special device to remove the polyp and seal the bowel wall closed afterwards.
View recommendations for IPG580Show all sections
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer (TA705)
Evidence-based recommendations on atezolizumab (Tecentriq) for treating advanced non-small-cell lung cancer in adults.
CerebAir for continuous EEG monitoring in intensive care (MIB279)
NICE has developed a medtech innovation briefing (MIB) on CerebAir for continuous EEG monitoring in intensive care .
Laser correction of refractive error following non-refractive ophthalmic surgery (IPG385)
Evidence-based recommendations on laser correction of refractive error following non-refractive ophthalmic surgery. This involves changing the shape of the cornea, so that light rays are more precisely directed onto the retina.
View recommendations for IPG385Show all sections
Sections for IPG385
The RhinoChill intranasal cooling system for reducing temperature after cardiac arrest (MIB4)
NICE has developed a Medtech Innovation Briefing (MIB) on the RhinoChill intranasal cooling system
This advice has been updated and replaced by NICE medical technologies guidance 44.
AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis (MIB46)
NICE has developed a medtech innovation briefing (MIB) on the AdenoPlus point-of-care test for diagnosing adenoviral conjunctivitis
This guideline covers assessing and managing non-complex fractures that can be treated in the emergency department or orthopaedic clinic. It aims to improve practice so that people with fractures receive the care that they need without unnecessary tests and treatments.
View recommendations for NG38Show all sections
Evidence-based recommendations on ivosidenib (Tibsovo) for treating locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation in adults after 1 or more systemic treatments.
NICE has developed a medtech innovation briefing (MIB) on Natural Cycles for monitoring fertility .
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
This advice has been updated and replaced by NICE medical technologies guidance 62.
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care
Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)
Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .